2023 was an exciting year for Optimum’s clients who overcame many of the market challenges to make significant strides forward with their vital life sciences research. Here are some of the highlights from what has been an exceptionally busy and successful year. M&A & deals Synaffix continued to build momentum – Lonza acquired the […]
Oslo, 09 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its third quarter 2023 results. Dr. Øystein Rekdal, Chief Executive Officer of Lytix Biopharma, commented: “We continue our efforts to demonstrate the clinical benefits of LTX-315 in patients with skin cancers. First and foremost, we are […]
Oslo, 17 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that the Research Council of Norway has approved Lytix’s application for up to NOK14.3m (US$1.3m) of non-dilutive financial support from the ‘SkatteFUNN’ R&D tax incentive scheme for a project in respect of its lead […]
Oslo, 9 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Henrik Jespersen, Head of Melanoma Oncology at Oslo University Hospital, will give a presentation of the NeoLIPA trial with LTX-315 at the 15th Nordic Melanoma Meeting (Reykjavik, 11-13 October 2023). The title […]
Oslo, 29 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has completed recruitment of 20 patients in the ATLAS-IT-05 trial – a trial evaluating LTX-315, Lytix’s lead drug candidate. Read more…..
